Indian generics drugmaker Dr Reddy’s Laboratories (NYSE: RDY) today reported its unaudited consolidated financial results for the quarter ended September 30, 2014, showing that revenues grew 7% to 35.88 billion rupees ($579 million).
Gross profit for the quarter rose 8% to 20.97 billion rupees, but pretax profit fell 10% to 6.94 billion rupees, or diluted earnings per share of 33.60 rupees, a drop of 17%. Dr Reddy’s shares dipped 1.1% to 3,046.35 rupees by late afternoon today.
Global generics
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze